soul trial oral semaglutide cardiovascular outcomes trial Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the Randomized Oral Semaglutide Cuts Cardiovascular Risk

Think of it this way: if your heart's electrical system is like a house's wiring, a B12 deficiency might cause a "brownout" (like anemia-induced tachycardia), but there could be other wiring issues your device can spot, too

Many telehealth GLP-1 providers operate with a similar model where the base price covers medication and minimal oversight, with more intensive medical management available at additional cost

S., Whiteman, M., Yang, H., Jones, D

PTD-DBM is not FDA approved for any indication

This ongoing assessment provides valuable insights into how effective the medications are and helps in making any necessary adjustments to their treatment plans

Dagan et al., 1997